Shimon Slavin

14.3k total citations · 4 hit papers
164 papers, 9.8k citations indexed

About

Shimon Slavin is a scholar working on Hematology, Immunology and Oncology. According to data from OpenAlex, Shimon Slavin has authored 164 papers receiving a total of 9.8k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Hematology, 80 papers in Immunology and 32 papers in Oncology. Recurrent topics in Shimon Slavin's work include Hematopoietic Stem Cell Transplantation (100 papers), Immune Cell Function and Interaction (45 papers) and Immunotherapy and Immune Responses (37 papers). Shimon Slavin is often cited by papers focused on Hematopoietic Stem Cell Transplantation (100 papers), Immune Cell Function and Interaction (45 papers) and Immunotherapy and Immune Responses (37 papers). Shimon Slavin collaborates with scholars based in Israel, United States and Italy. Shimon Slavin's co-authors include Arnon Nagler, Reuven Or, Memet Aker, Aliza Ackerstein, Gàbor Varadi, Simcha Samuel, Avraham Amar, E Naparstek, Gabriel Cividalli and Mark Kirschbaum and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Shimon Slavin

164 papers receiving 9.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases

1998 1.6k citations Shimon Slavin, Arnon Nagler et al. profile →
Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases

1998 1.5k citations Shimon Slavin, Arnon Nagler et al. profile →
Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning

2002 808 citations Alessandro Aiuti, Shimon Slavin et al. profile →
Safety and Immunological Effects of Mesenchymal Stem Cell Transplantation in Patients With Multiple Sclerosis and Amyotrophic Lateral Sclerosis

2010 709 citations Shimon Slavin et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shimon Slavin Israel	41	4.6k	2.9k	2.4k	2.3k	2.3k	164	9.8k
Shelly Heimfeld United States	38	4.1k 0.9×	3.5k 1.2×	3.2k 1.4×	2.9k 1.3×	1.7k 0.7×	107	9.8k
Daniel C. Link United States	62	4.9k 1.1×	5.4k 1.8×	4.2k 1.8×	3.1k 1.3×	2.5k 1.1×	209	13.3k
Roel Willemze Netherlands	59	7.3k 1.6×	5.4k 1.9×	3.4k 1.4×	3.9k 1.7×	3.3k 1.4×	288	14.3k
Christa Fonatsch Germany	49	4.0k 0.9×	1.1k 0.4×	2.9k 1.2×	1.2k 0.5×	1.8k 0.8×	197	7.7k
Richard A. Nash United States	48	4.9k 1.1×	2.7k 0.9×	833 0.4×	1.6k 0.7×	1.1k 0.5×	176	7.8k
Curt I. Civin United States	49	3.4k 0.7×	1.7k 0.6×	4.9k 2.1×	2.0k 0.8×	1.4k 0.6×	202	9.3k
Francesco Dazzi United Kingdom	57	3.9k 0.9×	2.8k 1.0×	2.3k 1.0×	2.2k 0.9×	6.1k 2.7×	173	11.0k
Shunichi Kato Japan	43	3.0k 0.6×	2.2k 0.7×	1.4k 0.6×	956 0.4×	1.1k 0.5×	171	6.2k
D. Robert Sutherland Canada	41	3.1k 0.7×	2.3k 0.8×	2.5k 1.0×	1.5k 0.6×	1.2k 0.5×	97	7.3k
Mark J. Kiel United States	26	3.1k 0.7×	2.0k 0.7×	2.9k 1.2×	1.7k 0.7×	1.5k 0.7×	37	7.2k

Countries citing papers authored by Shimon Slavin

Since Specialization

Citations

This map shows the geographic impact of Shimon Slavin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shimon Slavin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shimon Slavin more than expected).

Fields of papers citing papers by Shimon Slavin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shimon Slavin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shimon Slavin. The network helps show where Shimon Slavin may publish in the future.

Co-authorship network of co-authors of Shimon Slavin

This figure shows the co-authorship network connecting the top 25 collaborators of Shimon Slavin. A scholar is included among the top collaborators of Shimon Slavin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shimon Slavin. Shimon Slavin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lee, Hae Kyung, Ariel Bier, Simona Cazacu, et al.. (2013). MicroRNA-145 Is Downregulated in Glial Tumors and Regulates Glioma Cell Migration by Targeting Connective Tissue Growth Factor. PLoS ONE. 8(2). e54652–e54652. 92 indexed citations

Eitan, Erez, et al.. (2012). Novel telomerase‐increasing compound in mouse brain delays the onset of amyotrophic lateral sclerosis. EMBO Molecular Medicine. 4(4). 313–329. 75 indexed citations

Yarkoni, Shai, Tatyana B. Prigozhina, Shimon Slavin, & Nadir Askenasy. (2012). IL-2–Targeted Therapy Ameliorates the Severity of Graft-versus-Host Disease: Ex Vivo Selective Depletion of Host-Reactive T Cells and In Vivo Therapy. Biology of Blood and Marrow Transplantation. 18(4). 523–535. 12 indexed citations

Selleri, Silvia, Immacolata Brigida, Miriam Casiraghi, et al.. (2011). In vivo T-cell dynamics during immune reconstitution after hematopoietic stem cell gene therapy in adenosine deaminase severe combined immune deficiency. Journal of Allergy and Clinical Immunology. 127(6). 1368–1375.e8. 8 indexed citations

Uziel, Orit, Einat Beery, Sergei Gryaznov, et al.. (2010). Telomere Shortening Sensitizes Cancer Cells to Selected Cytotoxic Agents: In Vitro and In Vivo Studies and Putative Mechanisms. PLoS ONE. 5(2). e9132–e9132. 33 indexed citations

Resnick, Igor, Memet Aker, Simcha Samuel, et al.. (2009). A Retrospective Review of the Outcome after Second or Subsequent Allogeneic Transplantation. Biology of Blood and Marrow Transplantation. 15(4). 483–489. 25 indexed citations

Bitan, Menachem, Lola Weiss, Michael Zeira, et al.. (2008). Heparanase prevents the development of type 1 diabetes in non‐obese diabetic mice by regulating T‐cell activation and cytokines production. Diabetes/Metabolism Research and Reviews. 24(5). 413–421. 15 indexed citations

Aiuti, Alessandro, Barbara Cassani, Grazia Andolfi, et al.. (2007). Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. Journal of Clinical Investigation. 117(8). 2233–2240. 180 indexed citations

Abdul‐Hai, Ali, et al.. (2006). Interleukin 2 regulation following semi-allogeneic bone marrow transplantation in mice. Cancer Immunology Immunotherapy. 55(11). 1330–1336. 3 indexed citations

10.

Bitan, Menachem, Michael Y. Shapira, Igor Resnick, et al.. (2005). Successful transplantation of haploidentically mismatched peripheral blood stem cells using CD133+-purified stem cells. Experimental Hematology. 33(6). 713–718. 27 indexed citations

11.

Panigrahi, Soumya, et al.. (2004). A novel approach for prevention of lethal GVHD by selective elimination of alloreactive donor lymphocytes prior to stem cell transplantation. Experimental Hematology. 32(8). 756–764. 9 indexed citations

12.

Prigozhina, Tatyana B., et al.. (2004). Prevention of diabetes in nonobese diabetic mice by nonmyeloablative allogeneic bone marrow transplantation. Experimental Hematology. 32(6). 579–584. 23 indexed citations

13.

Slavin, Shimon, Shoshana Morecki, Lola Weiss, & Reuven Or. (2002). Donor Lymphocyte Infusion: The Use of Alloreactive and Tumor-Reactive Lymphocytes for Immunotherapy of Malignant and Nonmalignant Diseases in Conjunction with Allogeneic Stem Cell Transplantation. Journal of Hematotherapy & Stem Cell Research. 11(2). 265–276. 40 indexed citations

14.

Shapira, Michael Y., Allan I. Bloom, Reuven Or, et al.. (2002). Intra‐arterial catheter directed therapy for severe graft‐versus‐host disease. British Journal of Haematology. 119(3). 760–764. 20 indexed citations

15.

Weiss, Lola, et al.. (2002). Linomide administration following bone marrow transplantation in mice. Cancer Immunology Immunotherapy. 51(11-12). 596–602. 2 indexed citations

16.

Morecki, Shoshana & Shimon Slavin. (2000). Toward Amplification of a Graft-Versus-Leukemia Effect While Minimizing Graft-Versus-Host Disease. Journal of Hematotherapy & Stem Cell Research. 9(3). 355–366. 15 indexed citations

17.

Nagler, Arnon, et al.. (1999). The use of Soybean Agglutinin (SBA) for Bone Marrow (BM) purging and hematopoietic progenitor cell enrichment in clinical bone-marrow transplantation. Molecular Biotechnology. 11(2). 181–194. 3 indexed citations

18.

Morecki, Shoshana, Yael Gelfand, Arnon Nagler, et al.. (1997). Activated Long-Term Peripheral Blood Cultures as Preparation for Adoptive Alloreactive Cell Therapy in Cancer Patients. Journal of Hematotherapy. 6(2). 115–124. 11 indexed citations

19.

Ben‐Yosef, Rami, Reuven Or, E Naparstek, et al.. (1997). Should Soybean Agglutinin Purging Be Performed in Breast Cancer Patients Undergoing Autologous Stem Cell Transplantation?. American Journal of Clinical Oncology. 20(4). 419–423. 4 indexed citations

20.

Morecki, Shoshana, Shlomo Margel, & Shimon Slavin. (1988). Removal of breast cancer cells by soybean agglutinin in an experimental model for purging human marrow.. PubMed. 48(16). 4573–7. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact